![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer |
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok |
Cancer Research and Treatment. 2018;50(3):691-700. Published online 2017 July 6 DOI: https://doi.org/10.4143/crt.2017.280 |
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer Estimating the Budget Impact of Crizotinib for Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Argentina Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer FACTORS ASSOCIATED WITH CRIZOTINIB EFFICACY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING DIFFERENT ALK FUSION VARIANTS 174P: Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC) Corrigendum to “Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer” [Lung Cancer 121 (July) (2018) Pages 37–40] |
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014. |